The clinical trial (HERITAGE) was a double blind, prospective randomized trial that enrolled over 450 patients with HER2-positive advanced breast cancer and who never received prior chemotherapy or an anti-HER2 agent for their metastatic disease. Here, ERBB2 is linked to breast cancer.